Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors (STAT-PD)
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With Statins
Sponsor: Oregon Health and Science University
Listed as NCT04064294, this observational or N/A phase trial focuses on Dyskinesia, Drug-Induced and Parkinson Disease and remains completed. Sponsored by Oregon Health and Science University, it has been updated 14 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
May 2025 — Present [monthly]
Completed
-
Sep 2024 — May 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Aug 2023 — Jul 2024 [monthly]
Recruiting
-
Feb 2023 — Aug 2023 [monthly]
Recruiting
▶ Show 9 earlier versions
-
Jun 2022 — Feb 2023 [monthly]
Recruiting
-
Dec 2021 — Jun 2022 [monthly]
Recruiting
-
Mar 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
-
May 2020 — Oct 2020 [monthly]
Active Not Recruiting
Status: Suspended → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Suspended
Status: Recruiting → Suspended
-
Sep 2019 — Apr 2020 [monthly]
Recruiting
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oregon Health and Science University
- VA Office of Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .